StockWatch
·

KOPRAN LTD. Q2 FY27 Results

KOPRANQ2 FY27 Results
Filing
Result:Good· Market: Down#Turnaround#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue211.2637.2%79.2%
Total Income211.8935.8%79.7%
Expenditure205.9939.9%59.0%
PBT5.8933.1%150.7%
Net Profit4.3934.4%144.3%
OPM7.30%2.96pp11.78pp
NPM2.07%2.22pp10.48pp
EPS0.9134.5%55.8%
View full financials

Pharma revenue +79.2% YoY on a genuine loss-to-profit operating turnaround (no exceptional items), but core profitability lens shows margin give-back sequentially (OPM 7.3% vs 10.3% QoQ, PAT down 34.4% QoQ) on rising finance/depreciation costs, keeping it in the good rather than very_good band.

Q2 FY-2027 RESULTS · KOPRAN

Kopran turns profitable YoY in Q2 FY27 — consol PAT ₹4.4 Cr vs loss; revenue up 79%

revenue +79.2% · margins expanding

03 Nov 2026 · 3 min read
Revenue

₹211.26 Cr

+79.2% YoY

PAT (consolidated)

₹4.39 Cr

Net margin

2.07%

+10.5pp YoY

EPS

₹0.91

Kopran's consolidated Q2 FY27 (quarter ended September 30, 2026) print is a clean year-on-year turnaround: PAT of ₹4.39 Cr against a ₹9.92 Cr loss in Q2 FY26, on revenue up 79.2% YoY to ₹211.26 Cr. Neither period carries exceptional items, so the swing is operating, not one-off driven. Sequentially, though, the quarter cooled off — PAT fell 34.4% from ₹6.70 Cr in Q1 FY27 even as revenue kept climbing 37.2% QoQ, and OPM slipped to ~7.3% from 10.3% in Q1 FY27 (still well above the -4.5% a year ago), with NPM easing to 2.1% from 4.3% QoQ. Standalone tells a better bottom-line story — PAT of ₹6.29 Cr (EPS ₹1.30) versus the group's ₹4.39 Cr (EPS ₹0.91) — a gap the auditor's limited review traces to roughly a ₹2.1 Cr quarterly net loss at one overseas subsidiary; readers comparing the two numbers should note this is why they diverge rather than assume an error.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹211.26 Cr+37.2%+79.2%
Expenses₹205.99 Cr+39.9%+59%
PAT₹4.39 Cr-34.4%—
Net margin2.07%-2.2pp+10.5pp
EPS₹0.91-34.5%-55.8%

There is no prior guidance or concall commentary on record for Kopran, and a web search turned up no analyst or consensus estimates for this quarter either — both the guidance and street checks resolve to unknown for lack of coverage on this smallcap. The margin give-back sits mainly in the cost lines rather than other income: finance costs and depreciation both grew faster than other income on a rising capex and borrowings base, consistent with the company scaling up even as near-term profitability gave back part of Q1's gain. The quarter's one concrete regulatory datapoint — the EU GMP inspection at the Khopoli facility concluding successfully on October 22, 2026 — is a relevant quality-compliance signal alongside this quarter's growth, though the filing reports a single pharmaceuticals segment under Ind AS 108 with no revenue break-up to size its contribution. No management press release was available to cross-check against the reported numbers.

₹
158.34194.92231.5268.08304.66234.307-3108-2409-1610-0911-03Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹234.3, down 17.5% over the past month of trading.

₹ Cr
-13.38-1.4810.4222.327.45Q1 FY26rev ₹135 Cr-9.92Q2 FY26rev ₹118 Cr9.34Q3 FY26rev ₹194 Cr18.87Q4 FY26rev ₹234 Cr6.7Q1 FY27rev ₹154 Cr4.39Q2 FY27rev ₹211 Cr
Quarterly consolidated PAT, ₹ Crore
  • W1

    Whether OPM holds above ~7% or recovers toward Q1 FY27's 10.3% as the growth base normalizes in H2 FY27.

  • W2

    Scale/resolution of the loss-making overseas subsidiary (~₹2.1 Cr quarterly net loss per the auditor's review) dragging consolidated PAT below standalone.

  • W3

    Follow-through from the successfully concluded EU GMP inspection at Khopoli into order flow or capacity utilization in coming quarters.

Rs. in Lakhs in source; a small Foreign Exchange Gain (Net) line (nil for consolidated this quarter, ₹1.52 Lakh for standalone) is folded into otherIncome. No exceptional items in current or year-ago quarter. Consolidated PAT trails standalone because an overseas subsidiary posted a ~₹2.1 Cr quarterly net loss per the auditor's limited review report; figures are unaudited (limited review only).

Informational and educational content only. Not investment advice.